Join to access to all OVN content. Join for Free
Season 1, Episode 23: Revolutionizing Cancer Treatment with Paul Romness

Season 1, Episode 23: Revolutionizing Cancer Treatment with Paul Romness


Share This Article


Welcome back to the Pharmaverse, where we speak to the greatest voices in Pharma, to learn from their leadership and incredible careers! In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Paul Romness, CEO of OS Therapies. The conversation delves into the inspiring story behind OS Therapies, which was founded in response to the osteosarcoma diagnosis of Olivia, a close friend of Paul’s daughter. We talk how to build incredible cultures! "The culture is set by the mission.” Paul discusses the innovative HER2 technology being developed to treat osteosarcoma and the importance of nonprofit partnerships in advancing research. He also shares insights into the ADC technology and its potential applications in cancer treatment. Throughout the discussion, Paul emphasizes the significance of leadership, company culture, and the personal sacrifices made in pursuit of a mission-driven approach to improving patient outcomes. Tune in to listen to the most incredible episode!

🟨 Takeaways

👧 OS Therapies was inspired by a personal story of a young girl named Olivia.

🧬 The HER2 technology aims to enhance overall survival rates in osteosarcoma patients.

📚 Nonprofit partnerships play a crucial role in funding and advancing research.

💉 ADC technology is a promising area in cancer treatment.

✅❌Leadership is shaped by experiences with both good and bad mentors.

🩺Company culture is driven by a mission focused on patient care.

🤝Hiring the right people is essential for maintaining a strong culture.

📱Networking is vital for finding passionate individuals to join the team.

💞Personal sacrifices are often necessary to pursue meaningful work.

🥅The ultimate goal is to improve treatment outcomes for pediatric cancer patients. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN